Mengke Xu

Mar 6, 2024 | onlinelibrary.wiley.com | Cheng Xu |Mengke Xu |Yuxuan Hu |Jing Liu

Although colorectal cancer diagnosed at early stage shows high curability, methods simultaneously possessing point-of-care testing ability and high sensitivity are limited. Here, we present an orally deliverable biomarker-activatable probe (termed as HATS) for early detection of orthotopic tumor via remote urinalysis.